Cargando…

Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children

BACKGROUND: Pharmacokinetics, safety and antiviral activity of twice-daily fosamprenavir with or without ritonavir were evaluated in 2- to 18-year-old protease inhibitor–naïve and -experienced HIV-1–infected children. METHODS: Serial pharmacokinetic samples were collected at week 2 and predose sampl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fortuny, Claudia, Duiculescu, Dan, Cheng, Katharine, Garges, Harmony P., Cotton, Mark, Tamarirt, Desamparados Pérez, Ford, Susan L., Wire, Mary Beth, Givens, Naomi, Ross, Lisa L., Lou, Yu, Perger, Teodora, Sievers, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Williams & Wilkins 2014
Materias:	HIV Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882305/ https://www.ncbi.nlm.nih.gov/pubmed/23811744 http://dx.doi.org/10.1097/INF.0b013e3182a1126a

Ejemplares similares

Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data
por: Cotton, Mark, et al.
Publicado: (2014)

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
por: Ross, Lisa L, et al.
Publicado: (2015)

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
por: Campo, R., et al.
Publicado: (2013)

Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting
por: Alvarez-Uria, Gerardo, et al.
Publicado: (2016)

Post-licensing safety of fosamprenavir in HIV-infected children in Europe†
por: Judd, Ali, et al.
Publicado: (2014)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
por: Hofstra, L. Marije, et al.
Publicado: (2016)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
por: Smith, Kimberly Y, et al.
Publicado: (2008)

Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008–2012: a prospective cohort study
por: Kan, Wei, et al.
Publicado: (2017)

Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C–Coinfected Persons
por: Brunet, Laurence, et al.
Publicado: (2016)

A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model
por: Nakagawa, Fumiyo, et al.
Publicado: (2016)

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients
por: Flamholc, Leo, et al.
Publicado: (2008)

An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen
por: Nelson, Blessie, et al.
Publicado: (2020)

Protocol for active safety monitoring of a cohort of patients using a dolutegravir-based antiretroviral regimen in Mozambique
por: Mussá, Merana, et al.
Publicado: (2021)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV Therapy
por: Tang, Michele W., et al.
Publicado: (2012)

Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials
por: Nachega, Jean B., et al.
Publicado: (2014)

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
por: Saeed, Sahar, et al.
Publicado: (2016)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study
por: Stringer, Jeffrey SA, et al.
Publicado: (2012)

Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy
por: Martínez-Bonet, Marta, et al.
Publicado: (2015)

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects
por: Letendre, Scott L., et al.
Publicado: (2014)

Antiretroviral therapy uptake and predictors of virological failure in patients with HIV receiving first-line and second-line regimens in Johannesburg, South Africa: a retrospective cohort data analysis
por: Gumede, Siphamandla Bonga, et al.
Publicado: (2022)

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study
por: Aboud, M, et al.
Publicado: (2010)

Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre, Malawi*
por: MacPherson, Peter, et al.
Publicado: (2012)

THE INFLUENCE OF HIV-1 SUBTYPES C, CRF31_BC AND B ON DISEASE PROGRESSION AND INITIAL VIROLOGIC RESPONSE TO HAART IN A SOUTHERN BRAZILIAN COHORT
por: Nunes, Cynara Carvalho, et al.
Publicado: (2014)

DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
por: Arruda, Liã Bárbara, et al.
Publicado: (2014)

Description of the cascade of care and factors associated with attrition before and after initiating antiretroviral therapy of HIV infected children in a cohort study in India
por: Alvarez-Uria, Gerardo
Publicado: (2014)

DISCORDANCE BETWEEN BODY MASS INDEX AND ANTHROPOMETRIC MEASUREMENTS AMONG HIV-1-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY AND WITH LIPOATROPHY/LIPOHYPERTROPHY SYNDROME
por: SOARES, Lismeia Raimundo, et al.
Publicado: (2015)

PRETERM BIRTH AND FETAL GROWTH RESTRICTION IN HIV-INFECTED BRAZILIAN PREGNANT WOMEN
por: dos REIS, Helena Lucia Barroso, et al.
Publicado: (2015)

Harm reduction interventions in HIV care: a qualitative exploration of patient and provider perspectives
por: Carlberg-Racich, Suzanne
Publicado: (2016)

A pilot study to evaluate the magnitude of association of the use of electronic personal health records with patient activation and empowerment in HIV-infected veterans
por: Crouch, Pierre-Cédric B., et al.
Publicado: (2015)

Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007
por: Biraro, Samuel, et al.
Publicado: (2013)

Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement
por: Lofano, Giuseppe, et al.
Publicado: (2018)

Older adults at high risk of HIV infection in China: a systematic review and meta-analysis of observational studies
por: Wang, Yuan Yuan, et al.
Publicado: (2020)

HIV and the eye
por: Gichuhi, Stephen, et al.
Publicado: (2020)

Clusters of sub-Saharan African countries based on sociobehavioural characteristics and associated HIV incidence
por: Merzouki, Aziza, et al.
Publicado: (2021)

Factors associated with incidence of stroke and heart failure among people living with HIV in Ghana: Evaluating Vascular Event Risk while on Long‐Term Antiretroviral Suppressive Therapy (EVERLAST) Study
por: Sarfo, Fred Stephen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vg5num1h9016bkpe97aoqqc1rj